SMMT250110C34000
- 0.00
- 0.000.00%
Summit Therapeutics Newsroom
Merck Rival Summit Draws New Buy From Truist on Deal Prospects
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Truist Financial Initiates Summit Therapeutics(SMMT.US) With Buy Rating, Announces Target Price $35
Express News | Summit Therapeutics Inc : Truist Securities Initiates Coverage With Buy Rating; Price Target $35
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Annual Review | The most powerful month saw a threefold increase! Looking back at the monthly explosive rise of US stocks in 2024, AI and Trump Trade swept the whole year, with three Stocks making the list twice.
The US stock market continues to rise in 2024, mainly due to two significant trends: the tech stock frenzy driven by the AI boom and Trump's return to the White House.
Here Are Morgan Stanley's Key Oncology Catalysts for 2025
Why Did Summit Therapeutics Inc. (SMMT) Jump Yesterday?
Where Will Summit Therapeutics Be in 5 Years?
Summit Therapeutics Shares Are Trading Higher. The Stock May Be Moving in Sympathy With Neurocrine Biosciences Which Received FDA Approval for CRESNESSITY.
Watching Summit Therapeutics; Traders Circulate Newsletter Mention
How Is The Market Feeling About Summit Therapeutics?
Summit Therapeutics Initiated at Overweight by Wells Fargo
Wells Fargo Initiates Summit Therapeutics(SMMT.US) With Buy Rating, Announces Target Price $30
Why Summit Therapeutics Stock Rocketed 6% Higher on Friday
Jefferies Initiates Summit Therapeutics(SMMT.US) With Buy Rating, Announces Target Price $31
Summit Expands Workers' Compensation Coverage to Illinois
Is Summit Therapeutics (NASDAQ:SMMT) Using Debt In A Risky Way?
Express News | Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)